Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Codexis, Merck Extend Enzyme Supply Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Codexis, Merck Extend Enzyme Supply Pact

To license and supply enzyme used in the manufacturing process for sitagliptin

Codexis, Inc. has signed an agreement extension with Merck Sharp & Dohme Corp., to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient in Merck’s JANUVIA and one of the active ingredients in Merck’s JANUMET.
 
Under a R&D agreement, Codexis and Merck used the CodeEvolver protein engineering platform technology to develop a customized enzyme to serve as a biocatalyst in the sitagliptin process. The resulting enzyme streamlined the manufacturing process and increased production yield, while reducing costs and waste. In 2012 the companies entered into a supply agreement for the enzyme.
 
“The extension of this contract, coming on the heels of our licensing agreement for the CodeEvolver technology, is yet another vote of confidence in our protein engineering technology,” said Codexis president and chief executive officer John Nicols. “We are proud to continue our long term collaboration with Merck.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters